Skip to main content
. 2018 Nov 16;9:2736. doi: 10.3389/fmicb.2018.02736

FIGURE 4.

FIGURE 4

Western blot analysis of PDDI2-GFP gene products. (A) Cells harboring YCp- and YEp-based plasmids in response to 20 mM CY treatment. (B) Dose response of YCpU-PDDI2-GFP-transformed cells in response to CY. (C) Response of YEpU-PDDI2-GFP-transformed cells in response to high CY doses. (D) Response of YEpU-PDDI2-GFP-transformed cells in response to low CY doses. (E) Cells harboring YCp- and YEp-based plasmids in response to 0.015% MMS treatment. (F) Dose response of YCpU-PDDI2-GFP-transformed cells in response to MMS. (G) Response of YEpU-PDDI2-GFP-transformed cells in response to high MMS doses. (H) Response of YEpU-PDDI2-GFP-transformed cells in response to low MMS doses. The experimental protocol is described in Materials and Methods and all treatments were for 2 h. The anti-GFP monoclonal antibody B-2 was purchased from Santa Cruz (sc-9996) and the yeast anti-Pgk1 polyclonal antibody was a generous gift from Dr. W. Li (Institute of Zoology, Chinese Academy of Sciences, Beijing).